Skip to main
RAPP

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics Inc has experienced positive momentum following its inaugural R&D Day and the favorable Phase 2a data released on September 8, which demonstrated significant improvements in therapeutic outcomes using RAP-219 for patients suffering from refractory focal onset epilepsy. Key data from the Phase 2 proof-of-concept study revealed clinically meaningful reductions in long episodes and clinical seizures, along with enhanced recovery metrics and daily function improvements over the treatment period. The observed efficacy of RAP-219, combined with a favorable reimbursement environment and increasing physician enthusiasm for novel therapies, indicates a promising market potential for the company's innovative approach to central nervous system disorders.

Bears say

Rapport Therapeutics Inc faces significant challenges in its clinical development, particularly regarding the efficacy of its lead product, RAP-219, which may be overestimated based on preliminary Phase 2a results, risking lower efficacy in upcoming Phase 3 trials. The company also confronts substantial competition from more advanced therapies in the epilepsy treatment landscape, alongside potential issues related to commercial adoption and unfavorable insurance coverage that could negatively impact revenue prospects. Furthermore, the necessity for additional funding to support clinical trials and operational costs, combined with inherent manufacturing risks, creates a precarious financial outlook for Rapport Therapeutics, hindering its ability to achieve profitability.

RAPP has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Strong Buy based on their latest research and market trends.

According to 5 analysts, RAPP has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.